<DOC>
	<DOCNO>NCT01131325</DOCNO>
	<brief_summary>This study determine number European Leukemia Network ( ELN ) guideline define treatment failure event time study entry CML-CP patient low imatinib trough concentration treat nilotinib .</brief_summary>
	<brief_title>Study Nilotinib Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Ph+ CMLCP within 12 month diagnosis Imatinib 400 mg qd 12 month Imatinib trough plasma concentration &lt; 850 ng/mL Patient meet response milestone include : 1 . CHR least minor CyR ( Ph+ ≤65 % ) 3 month diagnosis 2 . At least pCyR 6 month diagnosis ( Ph+ ≤35 % ) 3 . CCyR 12 month diagnosis Prior document failure event include : Loss CHR CCyR Less CHR ( stable disease disease progression ) 3 month diagnosis No CyR 6 month diagnosis Less PCyR 12 month diagnosis Prior accelerate phase blast phase CML Previously document T315I mutation Previous treatment tyrosine kinase inhibitor except imatinib . Patients treatment CML ( transplant ) except imatinib , hydroxyurea and/or anagrelide Impaired cardiac function ( refer Section 5.2 detail ) Patients receive therapy strong inhibitor CYP3A4 medication prolong QT interval either discontinue switched different medication prior start study drug . Any malignancy clinically significant require active intervention . Major surgery within 4 week prior Day 1 study recover prior surgery . Treatment investigational agent within 30 day Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Philadelphia chromosome positive</keyword>
	<keyword>Ph+</keyword>
	<keyword>chronic myelogenous leukemia chronic phase</keyword>
	<keyword>CML-CP</keyword>
	<keyword>low imatinib trough level</keyword>
</DOC>